Could a nasal swab curb unnecessary antibiotic use?

NCT ID NCT07748143

Completed Disease control Sponsor: Methodist Health System Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial examines whether using a quick nasal swab to check for MRSA bacteria can help doctors decide how long to treat pneumonia patients with the antibiotic vancomycin. The study compares the duration of therapy and costs before and after implementing this screening test. Participants are adults hospitalized with pneumonia who start vancomycin treatment. The goal is to see if the test leads to shorter, more cost-effective antibiotic use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRSA nasal screen (a swab test to detect MRSA bacteria)
What this could lead to: If effective, this screening approach could help doctors stop unnecessary vancomycin sooner, reducing side effects and healthcare costs.
What could go wrong: This is a small, early study, so results may not apply broadly. The test's accuracy and impact on patient outcomes remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MRSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

methicillin-resistant staphylococcus aureus infectious disease pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MRSA

Contacts and locations

Locations

Methodist Dallas Medical Center- Clinical Research Institute

Dallas, Texas, 75203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.